Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Oxford tests Parkinson's drug to unlock secrets of depression

NCT ID NCT07022366

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

Researchers at the University of Oxford are studying how pimavanserin, a drug used for Parkinson's disease, affects memory, emotional processing, and decision-making in 80 healthy adults aged 18-45. By blocking a specific serotonin receptor, the study aims to better understand brain chemistry that could lead to new depression treatments. Participants receive either a single dose of pimavanserin or a placebo and complete cognitive tasks.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Pimavanserin (10 mg single dose)
What this could lead to
If successful, this study could reveal how a specific serotonin receptor influences mood and thinking, pointing toward new depression treatments.
What could go wrong
This is an early-stage, small study in healthy volunteers, not patients. Results may not translate to real-world depression treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 80 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2025

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 45 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Willing and able to give informed consent for participation in the research * Aged 18-45 years * Good vision and hearing * Body mass index (BMI) within the range of 18-35kg/m2 (This is to ensure an appropriate pharmacokinetic profile for pimavanserin is achieved by all participants) * Sufficiently fluent in English to understand tasks * Willing to avoid drinking any alcohol the day before the research visit Exclusion Criteria: * Currently receiving or seeking treatment for any mental health condition * Any past or current history of severe and/or serious psychiatric disorder, including but not limited to schizophrenia, psychosis, bipolar affective disorder, severe major depressive disorder, obsessive compulsive disorder (covered in SCID-5 assessment in screening procedures) * ADHD requiring treatment with stimulant or other centrally-acting drugs * Regular alcohol consumption of more than 21 units per week * A head injury causing concussion or unconsciousness in the past 6 months * Pregnancy / intention to become pregnant during the study or breastfeeding * Any use of recreational drugs in the last three months * Participation in any other drug study in the last three months * Participation in any other study with the same tasks in the last year * History of cardiac disease or cardiac arrhythmias * Prolonged QTc interval on baseline ECG * Current usage of other drugs known to prolong QT interval including Class 1A or 3 antiarrhythmics, e.g. certain antibiotics (getifloxacin, moxifloxacin) * Current use of drugs that inhibit CYP3A4 (eg Clarithromycin. Diltiazem. Erythromycin. Fluconazole). Participants will be asked to avoid grapefruit juice in the week before the study. * Current use of psychoactive medication that in the opinion of the Chief Investigator may interfere with the study measures * History of, or current medical condition(s) which, in the opinion of the Investigator may interfere with the safety of the participant or the scientific integrity of the study, including epilepsy/seizures, brain injury, severe hepatic or renal disease, severe gastro-intestinal problems, Central Nervous System (CNS) tumours, severe neurological problems (e.g. Parkinson's disease; blackouts requiring hospitalisation); * Any physical (including visual and auditory), cognitive or language impairment that would make complying with the study protocol challenging * Excessive caffeine consumption, i.e., consumption higher than 8 cups of standard caffeinated drinks (tea, instant coffee) or higher than 6 cups of stronger coffee or other drinks containing methylxanthines such as coca cola or Red Bull per day; * Smoking \>10 cigarettes per day; or equivalent nicotine consumption * Participant who is unlikely to comply with the clinical study protocol or is unsuitable for any other reason, in the opinion of the chief investigator. * Inability to ingest up to 95mg of lactose Additional Exclusion Criteria for Participants in the Sleep Study Cohort: * Unable to undergo cardiac monitoring * Unable to wear the sleep patch device for full monitoring period * Implanted neurostimulator

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Healthy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Department of Psychiatry, University of Oxford

    RECRUITING

    Oxford, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.